Sai Life Sciences Limited, an innovator focused, Contract Research, Development and Manufacturing Organization (CRDMO) announced its financial results for the fourth quarter and full year ended March 31, 2025.

During FY25, the company posted Revenue from Operations at Rs. 1,695 crore as compared to Rs. 1,465 crore in FY24, an increase of 16 per cent. EBITDA stood at Rs. 425 crore for FY25 compared to Rs. 300 crore in FY24, an increase of 42 per cent. PAT stood at Rs. 170 crore for FY25 as compared to Rs. 83 crore in FY24, an increase of 105 per cent.

During Q4 FY25, Sai Life Sciences posted Revenue from Operations at Rs. 580 crore as compared to Rs. 439 crore in Q4 FY24, an increase of 32 per cent. EBITDA stood at Rs. 161 crore for Q4 FY25 as compared to Rs. 124 crore in Q4FY24, an increase of 30 per cent. PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57 per cent.

Commenting on the performance during the quarter, Krishna Kanumuri, Managing Director and CEO, Sai Life Sciences Limited, said, “We are pleased to report a strong performance for FY25, ably supported by solid execution, capacity expansion, and deeper engagement with our customers. Our integrated CRDMO model continues to add value, helping us deliver seamless solutions across the drug development lifecycle to our global and biotech partners.

One of the highlights of the year was the launch of our Peptide Research Centre, set up to meet the growing demand for complex peptide synthesis and conjugation. This investment marks another step forward in strengthening our capabilities to support next-generation therapeutics.

With India emerging as a strategic hub in global drug development, Sai Life Sciences is well-positioned to tap into new growth opportunities. We remain focused on investing in technology, infrastructure, and talent to stay aligned with the evolving needs of our clients.

As we step into FY26, our priorities remain clear - to expand our capabilities, improve execution, and deliver lasting value to our stakeholders.”

Siva Chittor, Director and Chief Financial Officer, Sai Life Sciences Limited added,” We are pleased to report a strong FY25 performance, driven by consistent momentum across our CDMO and CRO segments. Revenue grew by 16 per cent and our EBITDA margin expanded to 25 per cent, in line with our growth aspirations. Profit after tax grew by 105 per cent, supported by stable finance costs and operating leverage. With the completion of our planned Rs. 720 crore debt repayment, we have significantly strengthened our balance sheet and expect lower interest costs starting FY26.

Capex for the year stood at Rs. 408 crore, focused on enhancing our manufacturing footprint and expanding discovery capabilities.

We remain committed to disciplined execution and prudent capital allocation as we continue to build on our growth momentum and deliver long-term value to stakeholders.”